MEF2C (Ser222) Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-70151r |
| Product Name | MEF2C (Ser222) Antibody |
| Applications |
WB
|
| Specificity | Specific for endogenous levels of the ~51 kDa MEF2C protein phosphorylated at Ser222. Immunolabeling is completely eliminated by treatment with λ-phosphatase. |
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Bovine, Sheep, Chicken, Guinea Pig, Non-Human Primate |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser222 of human MEF2C, conjugated to keyhole limpet hemocyanin (KLH). |
| Modification Site | Ser222 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | Lot Dependent |
| Purification | Antigen Affinity purification from Pooled whole antiserum |
| Storage Buffer | 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage Condition | Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target | |
| Gene ID | 4208 |
| Swiss Prot | Q06413 |
| Synonyms | C5DELq14.3 antibody, DEL5q14.3 antibody, MADS box transcription enhancer factor 2 polypeptide C (myocyte enhancer factor 2C) antibody, MADS box transcription enhancer factor 2 polypeptide C antibody, MEF2C antibody, MEF2C_HUMAN antibody, Myocyte enhancer factor 2C antibody, Myocyte specific enhancer factor 2C antibody, Myocyte-specific enhancer factor 2C antibody, OTTHUMP00000222409 antibody, Similar to MADS box transcription enhancer factor 2 polypeptide C antibody |
| Background | MEF2C, also known as MADS box transcription enhancer factor 2, polypeptide C, is one of 4 MEF2 (myocyte enhancer factor 2) transcription factors that encode proteins for development of skeletal muscle and brain proliferation and differentiation (McDermott et al, 1993), along with regulating stress-response during cardiac hypertrophy in mammals (Wu et al, 2015). Phosphorylation of MEF2C at serine 59 has been shown to be negatively regulated by integrin-linked kinase (ILK) (Dong et al, 2015). Recently, high MEF2C expression has been associated with a subset of acute myeloid leukemia (AML) patients with adverse-risk disease features and poor outcomes (Laszlo et al, 2015). Phosphorylation of MEF2C at serine 222 may play a key role in MEF2C signaling. |
| Application Dilution | |
| WB | 1:300-5000 |